---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-011951"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T05:44:15.357910+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Replimune reports Q3 FY2024 net loss $51.1M; cash $466.4M; RP1 BLA plan for 2H 2024

## Summary
- Net loss of $51.1M for Q3 FY2024, up from $39.7M in prior year; R&D expenses $42.8M vs $30.3M.
- Cash, equivalents & short-term investments $466.4M as of Dec 31, 2023; cash runway extended into 2H 2026.
- BLA submission for RP1 in anti-PD1 failed melanoma planned for 2H 2024; Phase 3 confirmatory trial to start 2H 2024.
- RP2 data in uveal melanoma positive; planning for potential registrational trial in advanced uveal melanoma.

## SEC filing metadata
- accession: 0001104659-24-011951
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465924011951/0001104659-24-011951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465924011951/tm245513d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-011951
- JSON: https://secwatch.observer/filing/0001104659-24-011951.json
- Plain text: https://secwatch.observer/filing/0001104659-24-011951.txt

## Key facts
- Earnings Releases
  Replimune Group, Inc. reported financial results for third quarter ended December 31, 2023.
  - Period: third quarter ended December 31, 2023
  - Result: reported results
  source text: On February 8, 2024, Replimune Group, Inc. (the “Company”) issued a news release announcing its financial results for the third quarter ended December 31, 2023 and certain corporate updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737953/000110465924011951/0001104659-24-011951-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.